Jinbo Biotech Responds to Medical Aesthetics Exosome Chaos: "Medical Device Registration 3" is the True Injectable-Grade "Admission Certificate"

(Source: Qianlong News)

In response to the exposure of illegal practices involving external vesicle products in the “3.15” Gala, Shanxi Jinbo Biopharmaceutical Co., Ltd. (listed on the Beijing Stock Exchange as “Jinbo Biotech,” 920982.BJ) issued a statement on March 17th stating that the illegal activities of the exposed companies have no relation to Jinbo Biotech. At the same time, Jinbo Biotech urges consumers to recognize the three types of medical device registration certificates (i.e., “Medical Device Approval Number 3”) and stay away from illegal injection traps.

Jinbo Biotech stated that regarding the illegal “product licensing” and illegal injections of external vesicle products exposed in the “3.15” Gala in the aesthetic medicine industry, the company attaches great importance. It has received numerous calls and online inquiries from consumers and partners.

In the statement, Jinbo Biotech said, “The ‘Qingyang’ products produced by a certain biotech company reported in the ‘3.15’ Gala have been confirmed to be counterfeit, using a Type II medical device license for human-derived collagen, with illegal addition of vesicle components.” Jinbo Biotech has never produced or sold any injection products containing vesicle components and has no business relationship or cooperation with the exposed company.

Additionally, Jinbo Biotech emphasizes that Type II medical devices are not for human injection. The “Medical Device Approval Number 3” is the “license” for injectable-grade products.

According to their information, based on regulations from the National Medical Products Administration, any medical device injected into human dermis or bloodstream is classified as a high-risk Class III medical device, which must undergo rigorous pharmaceutical research, clinical trials, and review before being approved with a “Medical Device Approval Number 3” for market use. Class II medical devices are only suitable for non-invasive or superficial use and must not be used for injections.

From their perspective, Jinbo Biotech states that in the field of compliant recombinant human-derived collagen injection products, it is currently the only domestic company approved by the National Medical Products Administration with three Class III medical device registration certificates. The registration numbers are: Guo Xie Zhun 20213130488, Guo Xie Zhun 20233131245, and Guo Xie Zhun 20253130751.

Jinbo Biotech emphasizes that, as of now, China has not approved any vesicle-based drugs for market listing, nor has it approved any medical device products containing vesicles for sale. All products claiming to be injectable, anti-aging, or disease-treating vesicles are illegal, and their safety and efficacy are not recognized by the state. Consumers should be highly vigilant.

The official website shows that Jinbo Biotech is a company that has industrialized recombinant human-derived collagen and is also a national-level “Little Giant” specialized and innovative enterprise. On July 20, 2023, Jinbo Biotech listed on the A-share market, becoming the “First Stock of Recombinant Collagen” on the Beijing Stock Exchange.

The company’s performance brief on February 28 indicates that by the end of 2025, Jinbo Biotech achieved an operating revenue of approximately 1.595 billion yuan, a year-on-year increase of 10.57%; net profit attributable to shareholders of the listed company was about 65.1176 million yuan, a decrease of 11.08% year-on-year.

Regarding the main reasons for the change in net profit, Jinbo Biotech explained that, on one hand, the VAT rate for related medical devices increased from 3% to 13% starting January 1, 2025, affecting the after-tax sales revenue of relevant medical devices during the reporting period, which slowed the growth of medical device revenue; on the other hand, although the functional skincare business is developing rapidly and its revenue share has increased, its gross profit margin is lower than that of medical devices, leading to an adjustment in revenue structure and a decline in overall gross profit margin.

Wind data shows that as of March 18, Jinbo Biotech’s stock price was 180.57 yuan per share, a slight decrease of 0.02%, with a total market value of 20.78 billion yuan. Among the 298 companies listed on the Beijing Stock Exchange, it ranks third.